The Development Prospect of guilin sanjin Pharmaceutical Co., Ltd.

Facing the challenge of China's entry into WTO, Sanjin Pharmaceutical Co., Ltd. will adhere to the concept of "caring for life and health", actively promote and implement the modernization plan of Chinese medicine industry, and seize the opportunity of the country to develop Chinese medicine industry and Guangxi to list medicine as a key pillar industry in the autonomous region. While actively improving the research and development level of enterprise technology centers, we should increase cooperation with scientific research institutes, rely on the rich resources of Chinese herbal medicines in Guangxi, and take the traditional Chinese medicine theory as the guidance. By means of modern science and technology, we will develop modern Chinese medicine preparations with high curative effect, high quality, high technology and controllable quality, which can meet the market demand at home and abroad, and build Sanjin into a leading domestic and world-class R&D and production enterprise of Chinese medicine and natural medicine, and promote the modernization of Chinese medicine industry.

After three years' in-depth investigation of the 2009 version of the catalogue, the long-awaited 20 12 version of the national essential drugs catalogue was recently unveiled and officially released. Guilin sanjin, as a leading pharmaceutical enterprise in Guangxi, its main exclusive varieties Sanjin tablets and Gejiedingchuan capsules have been selected into the national list of essential drugs in recent years. After the publication of the new version of the list of essential drugs, it will be officially implemented on May 1 this year, and all provinces in China will issue regulations to determine the proportion of essential drugs used by medical and health institutions at all levels. It can be predicted that all varieties selected by guilin sanjin in the new national essential drugs list will increase in quantity, and their sales market will be effectively broadened, providing more positive energy for its 20 13 annual and future performance, which will be a great benefit for the company's subsequent development.